Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods

Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods REVIEW ARTICLE Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods Rajendra B. Shahi, MSc,* Sylvia De Brakeleer, MSc,* Jacques De Gre`ve, MD, PhD,* Caroline Geers, MD,w Peter In’t Veld, PhD,w and Erik Teugels, PhD* pidermal growth factor receptor (EGFR), the mam- Abstract: Somatic mutations in the epidermal growth factor Emalian homolog of avian viral oncoprotein v-erbB, is a receptor-tyrosine kinase (EGFR-TK) domain of non–small cell member of the ErbB family found normally on the surface lung cancer (NSCLC) influence the responsiveness of these tu- of the epithelial cells and is responsible for the regulation mors to EGFR-TK inhibitors, indicating their usefulness as a of a number of cellular processes such as proliferation, 1–4 predictive molecular marker. However, for mutation analysis, motility, and survival. Mutation of the EGFR gene in the amount of clinical material available from NSCLC patients non–small cell lung cancer (NSCLC) is considered to be is often very limited, suboptimally preserved, and composed of an indicator for differential clinical responses to reversible both normal and tumor cells. As a consequence, the total tyrosine kinase (TK) inhibitors such as gefitinib and 5–7 amount of recovered DNA is frequently very limited, with erlotinib. Therefore, the screening http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods

Loading next page...
 
/lp/wolters-kluwer-health/detection-of-egfr-tk-domain-ndash-activating-mutations-in-nsclc-with-FGlfyjzgy1

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
eISSN
1533-4058
DOI
10.1097/PDM.0000000000000035
pmid
25751592
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods Rajendra B. Shahi, MSc,* Sylvia De Brakeleer, MSc,* Jacques De Gre`ve, MD, PhD,* Caroline Geers, MD,w Peter In’t Veld, PhD,w and Erik Teugels, PhD* pidermal growth factor receptor (EGFR), the mam- Abstract: Somatic mutations in the epidermal growth factor Emalian homolog of avian viral oncoprotein v-erbB, is a receptor-tyrosine kinase (EGFR-TK) domain of non–small cell member of the ErbB family found normally on the surface lung cancer (NSCLC) influence the responsiveness of these tu- of the epithelial cells and is responsible for the regulation mors to EGFR-TK inhibitors, indicating their usefulness as a of a number of cellular processes such as proliferation, 1–4 predictive molecular marker. However, for mutation analysis, motility, and survival. Mutation of the EGFR gene in the amount of clinical material available from NSCLC patients non–small cell lung cancer (NSCLC) is considered to be is often very limited, suboptimally preserved, and composed of an indicator for differential clinical responses to reversible both normal and tumor cells. As a consequence, the total tyrosine kinase (TK) inhibitors such as gefitinib and 5–7 amount of recovered DNA is frequently very limited, with erlotinib. Therefore, the screening

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2015

There are no references for this article.